Page last updated: 2024-12-09
icd 1578
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
7-N-phenylcarbamoylamino-4-chloro-3-propyloxyisocoumarin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 577033 |
| CHEMBL ID | 140958 |
| SCHEMBL ID | 7311335 |
| MeSH ID | M0292560 |
Synonyms (13)
| Synonym |
|---|
| 7-phenylureido-4-chloro-3-propyloxyisocoumarin |
| CHEMBL140958 |
| 00541o72ry , |
| icd-1578 |
| 140653-02-7 |
| urea, n-(4-chloro-1-oxo-3-propoxy-1h-2-benzopyran-7-yl)-n'-phenyl- |
| unii-00541o72ry |
| SCHEMBL7311335 |
| NTIRQLXQCVZDJU-UHFFFAOYSA-N |
| 4-chloro-7-(3-phenylureido)-3-(propyloxy)-1h-2-benzopyran-1-one |
| n-(4-chloro-1-oxo-3-propoxy-1h-isochromen-7-yl)-n'-phenylurea # |
| 7-n-phenylcarbamoylamino-4-chloro-3-propyloxyisocoumarin |
| Q27231318 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID52459 | The second order inactivation rate constant was expressed as inhibition of chymotrypsin (ChT). Inhibitor concentrations were 3.4-70 uM | 1995 | Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3 | Mechanism-based isocoumarin inhibitors for human leukocyte elastase. Effect of the 7-amino substituent and 3-alkoxy group in 3-alkoxy-7-amino-4-chloroisocoumarins on inhibitory potency. |
| AID155080 | The second order inactivation rate constant was expressed as inhibition of porcine pancreatic elastase (PPE). Inhibitor concentrations were 34-56 uM | 1995 | Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3 | Mechanism-based isocoumarin inhibitors for human leukocyte elastase. Effect of the 7-amino substituent and 3-alkoxy group in 3-alkoxy-7-amino-4-chloroisocoumarins on inhibitory potency. |
| AID67482 | Inhibition of human leukocyte elastase(HLE) at 0.7-1.7 uM | 1995 | Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3 | Mechanism-based isocoumarin inhibitors for human leukocyte elastase. Effect of the 7-amino substituent and 3-alkoxy group in 3-alkoxy-7-amino-4-chloroisocoumarins on inhibitory potency. |
| AID42661 | In vitro inhibitory potency was tested against botulinum neurotoxin/B (BoNT/B) expressed as Ki | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22 | Development of potent inhibitors of botulinum neurotoxin type B. |
| AID23826 | Rate of deacylation in porcine pancreatic elastase (PPE). | 1995 | Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3 | Mechanism-based isocoumarin inhibitors for human leukocyte elastase. Effect of the 7-amino substituent and 3-alkoxy group in 3-alkoxy-7-amino-4-chloroisocoumarins on inhibitory potency. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||